直接抗病毒药物时代丙型肝炎病毒相关肝细胞癌的诊治对策  

Diagnosis and treatment strategies of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antiviral drugs

作　　者：高旭 纪泛扑[1] Gao Xu;Ji Fanpu(Department of Infectious Disease,the Second Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710004,China)

机构地区：[1]西安交通大学第二附属医院感染科,710004

出　　处：《中华肝脏病杂志》2020年第10期827-830,共4页Chinese Journal of Hepatology

基　　金：国家自然科学基金(81300322);西安交通大学医学部国家级后备人选菁英计划(305);陕西省自然科学基础研究计划(2017JM8092)。

摘　　要：慢性丙型肝炎(CHC)隐匿进展是导致肝硬化和肝细胞癌(HCC)的主要原因之一。近年来,随着直接抗病毒药物(DAAs)的问世,CHC尤其是特殊人群包括进展期肝病和HCC的抗病毒治疗取得了巨大进展。DAAs和HCC的相关问题也成为目前CHC治疗的重要关注点之一。现就近年来丙型肝炎相关HCC诊治的最新研究进展进行综述。The occult progression of chronic hepatitis C(CHC)is one of the main causes of liver cirrhosis and hepatocellular carcinoma(HCC).Recently,antiviral treatment of CHC has achieved great progress with the advent of direct-acting antiviral drugs(DAA),especially for special populations including advanced liver disease and HCC.However,DAA and HCC-related issues have also become one of the important concerns of current CHC treatment.This article summarizes the recent research progresses made in the diagnosis and treatment of HCV-related HCC.

关 键 词：肝炎 丙型 慢性 肝细胞癌 直接抗病毒药物 诊疗策略 

分 类 号：R512.63[医药卫生—内科学] R735.7[医药卫生—临床医学]